

Supplementary Table 1: Prevalence of IBS per country

Country	References of studies	Total sample	Total IBS	Prevalence (%)
Canada	51,79	1,586	249	15.7
USA	5,24,54,70,74,75,76,84,	51,204	3,308	6.46
Mexico	52	500	80	40.0
Colombia	27	558	111	19.9
Peru	15,21	531	129	24.2
Chile	55	437	125	28.6
Brazil	72	183	31	16.9
Argentina	62	831	100	12.0
Uruguay	37	266	29	10.9
Iceland	61	1,336	413	30.9
Norway	81	4,622	388	8.4
Finland	32	3,631	184	5.1
Sweden	2,3,6,63,82	7,350	1,195	16.3
Denmark	68	47,174	4,939	10.5
UK	1,30,41,43,59,85	19,885	2,530	12.7
Netherlands	10	428	25	5.8
Germany	31,34,38	3,889	246	6.3
France	11,12,23	34,472	1,245	3.6
Italy	20,80,88	32,072	2,503	7.8
Spain	14,58	2,420	317	13.1
Greece	65	700	150	21.4
Croatia	8,26	1,203	346	28.7
Romania	25	338	49	14.5
Russia	69	1040	198	19.0
Turkey	9,16,42,87,	6,473	671	10.4
Israel	73	981	112	11.4
Iran	4,44,45	24,920	750	3.1
India	56	4,767	191	4.0
Pakistan	36,39	1,928	589	30.5
Bangladesh	57,66	3,929	322	8.2
Thailand	22	401	50	5.7
Singapore	17,28,33	3,243	222	6.8
Malaysia	67	949	148	15.6
Hongkong	47,48	2,298	114	4.9
Mainland China	18,49,64,83,86,89	29,288	1,341	4.6
Taiwan	53	2,018	447	22.1
Japan	35,46	15,020	1,789	11.9
South Korea	19,29,40,50	4,346	274	6.3
Australia	13,77,78	3,739	308	8.2
New Zealand	7	980	184	18.8
Nigeria	60	443	140	31.6
South Africa	71	332	27	8.1
42 countries	total No. of studies: 89	322,271	26,569	8.23

1. Aggarwal VR, McBeth J, Zakrzewska JM, et al. The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? *Int J Epidemiol* 2006;35:468–476.
2. Agréus L, Svärdsudd K, Nyrén O, et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. *Gastroenterology* 1995;109:671–680.
3. Agréus L, Talley NJ, Svärdsudd K, et al. Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors. *Scand J Gastroenterol* 2000;35:142–151.
4. Amra B, Hoseini-Asl MK, Rahmani AR, et al. Correlation between asthma and irritable bowel syndrome in a general population in Iran in 2003. *Respir Med* 2006;100:110–114.
5. Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large webbased survey. *Aliment Pharmacol Ther* 2005;22:935–942.
6. Aro P, Ronkainen J, Storskrubb T, et al. Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study. *Scand J Gastroenterol* 2004;39:1280–1288.
7. Barbezat G, Poulton R, Milne B, Howell S, Fawcett JP, Talley N. Prevalence and correlates of irritable bowel symptoms in a New Zealand birth cohort. *N Z Med J.* 2002 Oct 25;115(1164):U220.
8. Baretic M, Bilic A, Jurcic D, et al. Epidemiology of irritable bowel syndrome in Croatia. *Coll Antropol* 2002;26(Suppl):85–91.
9. Basaranoglu M, Celebi S, Ataseven H, et al. Prevalence and consultation behavior of self-reported rectal bleeding by faceto-face interview in an Asian community. *Digestion* 2008;77:10–15.
10. Boekema PJ, van Dam van Isselt EF, Bots ML, et al. Functional bowel symptoms in a general Dutch population and associations with a common stimulus. *Neth J Med* 2001;59:23–30.
11. Bommelaer G, Dorval E, Denis P, et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. *Gastroenterol Clin Biol* 2002;26:1118–1123.
12. Bommelaer G, Poynard T, Le Pen C, et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. *Gastroenterol Clin Biol* 2004;28:554–561.
13. Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? *Am J Gastroenterol* 2000;95:3176–3183.
14. Caballero-Plasencia AM, Sofos-Kontoyannis S, Valenzuela-Barranco M, et al. Irritable bowel syndrome in patients with dyspepsia: a community-based study in Southern Europe. *Eur J Gastroenterol Hepatol* 1999;11:517–522.
15. Campos Hurtado G, León Barúa R, Villareal Menchola J, et al. [Association between irritable intestinal syndrome and depressive symptoms in a population of high socioeconomic level of Lima]. *Rev Gastroenterol Peru* 2001;21:198–204.
16. Celebi S, Acik Y, Deveci SE, et al. Epidemiological features of irritable bowel syndrome in a Turkish urban society. *J Gastroenterol Hepatol* 2004;19:738–743.
17. Chen LY, Ho KY, Phua KH. Normal bowel habits and prevalence of functional bowel disorders in Singaporean adults: findings from a community based study in Bishan. *Singapore Med J* 2000;41:255–258.
18. Cheung TK, Lam KF, Hu WH, et al. Positive association between gastro-oesophageal reflux disease and irritable bowel syndrome in a Chinese population. *Aliment Pharmacol Ther* 2007;25: 1099–1104.
19. Choo KY, Choi MG, Choi H, et al. [The prevalence of gastrointestinal symptoms in a rural community in Korea]. *Korean J Gastrointest Motil* 2000;6:31–43.
20. Corazziari E, Attili AF, Angeletti C, et al. Gallstones, cholecystectomy and irritable bowel syndrome (IBS): MICOL populationbased study. *Dig Liver Dis* 2008;40:944–950.
21. Curioso WH, Mendoza ND, Zerpa CB, et al. [Prevalence and relation of dyspepsia to irritable bowel syndrome in a native community of the Peruvian jungle]. *Rev Gastroenterol Peru* 2002;22:129–140.

22. Danivat M, Tankeyoon M, Sriratanaban A. Prevalence of irritable bowel syndrome in a non-Western population. *BMJ* 1988;296:1710.
23. Dapoigny M, Bellanger J, Bonaz B, et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. *Eur J Gastroenterol Hepatol* 2004;16:995–1001.
24. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. *Dig Dis Sci* 1993;38:1569–1580.
25. Drug VL, Oprea L, Bunescu D, et al. The epidemiology of irritable bowel syndrome in an urban general population. *Rom J Gastroenterol* 2000;9:83–86.
26. Ebling B, Jurcic' D, Gmajnic' R, et al. Anthropological, demographic, and socioeconomic characteristics of irritable bowel syndrome. *Coll Antropol* 2011;35:513–521.
27. Gómez Alvarez DF, Morales Vargas JG, Rojas Medina LM, et al. [Prevalence of irritable bowel syndrome and associated factors according to the Rome III diagnostic criteria in a general population in Colombia]. *Gastroenterol Hepatol* 2009;32:395–400.
28. Gwee KA, Wee S, Wong ML, et al. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. *Am J Gastroenterol* 2004;99:924–931.
29. Han SH, Lee OY, Bae SC, et al. Prevalence of irritable bowel syndrome in Korea: population-based survey using the Rome II criteria. *J Gastroenterol Hepatol* 2006;21:1687–1692.
30. Heaton KW, O'Donnell LJ, Braddon FE, et al. Symptoms of irritable bowel syndrome in a British urban community: consulters and non-consulters. *Gastroenterology* 1992;102:1962–1967.
31. Herschbach P, Henrich G, von Rad M. Psychological factors in functional gastrointestinal disorders: characteristics of the disorder or the illness behavior? *Psychosom Med* 1999;61:148–153.
32. Hillilä MT, Färkkilä MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. *Aliment Pharmacol Ther* 2004;20:339–345.
33. Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. *Am J Gastroenterol* 1998;93:1816–1822.
34. Holtmann G, Goebell H, Talley NJ. Dyspepsia in consulters and non-consulters: prevalence, health-care seeking behaviour and risk factors. *Eur J Gastroenterol Hepatol* 1994;6:917–924.
35. Hongo M. Epidemiology of FGID symptoms in Japanese general population with reference to life style. *J Gastroenterol Hepatol* 2011;26(Suppl 3):19–22.
36. Husain N, Chaudhry IB, Jafri F, et al. A population-based study of irritable bowel syndrome in a non-Western population. *Neurogastroenterol Motil* 2008;20:1022–1029.
37. Iade B, Toma R. [The frequency of irritable bowel syndrome in a population of Montevideo]. *Arch Med Int* 2003;25:91-96
38. Icks A, Haastert B, Enck P, et al. Prevalence of functional bowel disorders and related health care seeking: a population-based study. *Z Gastroenterol* 2002;40:177–183.
39. Jafri W, Yakoob J, Jafri N, et al. Irritable bowel syndrome and health seeking behaviour in different communities of Pakistan. *J Pak Med Assoc* 2007;57:285–287.
40. Jeong JJ, Choi MG, Cho YS, et al. Chronic gastrointestinal symptoms and quality of life in the Korean population. *World J Gastroenterol* 2008;14:6388–6394.
41. Jones R, Lydeard S. Irritable bowel syndrome in the general population. *BMJ* 1992;304:87–90.
42. Karaman N, Türkay C, Yönm O. Irritable bowel syndrome prevalence in city center of Sivas. *Turk J Gastroenterol* 2003;14: 128–131.
43. Kennedy TM, Jones RH, Hungin AP, et al. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. *Gut* 1998;43:770–774.

44. Khademolhosseini F, Mehrabani D, Nejabat M, et al. Irritable bowel syndrome in adults over 35 years in Shiraz, southern Iran: prevalence and associated factors. *J Res Med Sci* 2011;16:200–206.
45. Khoshkrood-Mansoori B, Pourhoseingholi MA, Safaei A, et al. Irritable bowel syndrome: a population based study. *J Gastrointest Liver Dis* 2009;18:413–418.
46. Kumano H, Kaiya H, Yoshiuchi K, et al. Comorbidity of irritable bowel syndrome, panic disorder, and agoraphobia in a Japanese representative sample. *Am J Gastroenterol* 2004;99:370–376.
47. Kwan AC, Hu WH, Chan YK, et al. Prevalence of irritable bowel syndrome in Hong Kong. *J Gastroenterol Hepatol* 2002;17:1180–1186.
48. Lau EM, Chan FK, Ziea ET, et al. Epidemiology of irritable bowel syndrome in Chinese. *Dig Dis Sci* 2002;47:2621–2624.
49. Lee S, Wu J, Ma YL, et al. Irritable bowel syndrome is strongly associated with generalized anxiety disorder: a community study. *Aliment Pharmacol Ther* 2009;30:643–651.
50. Lee SY, Lee KJ, Kim SJ, et al. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. *Digestion* 2009;79:196–201.
51. Li FX, Patten SB, Hilsden RJ, et al. Irritable bowel syndrome and health-related quality of life: a population-based study in Calgary, Alberta. *Can J Gastroenterol* 2003;17:259–263.
52. López-Colombo A, Morgan D, Bravo-González D, Montiel-Jarquín A, Méndez-Martínez S, Schmulson M. The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. *Gastroenterol Res Pract.* 2012;2012:606174.
53. Lu CL, Chen CY, Lang HC, Luo JC, Wang SS, Chang FY, Lee SD. Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. *Aliment Pharmacol Ther.* 2003 Dec;18(11-12):1159-69
54. Lydiard RB, Greenwald S, Weissman MM, et al. Panic disorder and gastrointestinal symptoms: findings from the NIMH epidemiologic catchment area project. *Am J Psychiatry* 1994;151:64–70.
55. Madrid-Silva AM, Defilippi-Caffri C, Landskron-Ramos G, Olgún-Herrera F, Reyes-Ponce A, Castro-Lara A, Larrain-Corp S, Martínez-Roje N, Cortés-Espinoza J. [The prevalence of irritable bowel symptoms in a population of shopping mall visitors in Santiago de Chile]. *Rev Gastroenterol Mex.* 2013 Oct-Dec;78(4):203-10.
56. Makharia GK, Verma AK, Amarchand R, Goswami A, Singh P, Agnihotri A, Suhail F, Krishnan A. Prevalence of irritable bowel syndrome: a community based study from northern India. *J Neurogastroenterol Motil.* 2011 Jan;17(1):82-7.
57. Masud MA, Hasan M, Khan AK. Irritable bowel syndrome in a rural community in Bangladesh: prevalence, symptom pattern, and health care seeking behavior. *Am J Gastroenterol* 2001;96:1547–1552.
58. Mearin F, Badía X, Balboa A, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. *Scand J Gastroenterol* 2001;36:1155–1161.
59. Nicholl BI, Halder SL, MacFarlane GJ, et al. Psychosocial risk markers for new onset irritable bowel syndrome: results of a large prospective population-based study. *Pain* 2008;137:147–155.
60. Okeke EN, Ladep NG, Adah S, et al. Prevalence of irritable bowel syndrome: a community survey in an African population. *Ann Afr Med* 2009;8:177–180.
61. Olafsdóttir LB, Gudjónsson H, Thjódleifsson B. [Epidemiological study of functional bowel disorders in Iceland]. *Laeknabladid* 2005;91:329–333.
62. Olmos JA, Guzmán M, Gadea O, et al. Irritable bowel syndrome: prevalence, comorbidity and impact. A population based study. *Gut.* 2010;59, supplement 3:p. A361

63. Osterberg E, Blomquist L, Krakau I, et al. A population study on irritable bowel syndrome and mental health. *Scand J Gastroenterol* 2000;35:264–268.
64. Pan G, Lu S, Ke M, et al. Epidemiologic study of the irritable bowel syndrome in Beijing: stratified
65. Papatheoridis GV, Karamanolis DG. Prevalence and impact of upper and lower gastrointestinal symptoms in the Greek urban general population. *Scand J Gastroenterol* 2005;40:412–421.
66. Perveen I, Hasan M, Masud MA, et al. Irritable bowel syndrome in a Bangladeshi urban community: prevalence and health care seeking pattern. *Saudi J Gastroenterol* 2009;15:239–243.
67. Rajendra S, Alahuddin S. Prevalence of irritable bowel syndrome in a multi-ethnic Asian population. *Aliment Pharmacol Ther* 2004;19:707–708.
68. Rasmussen S, Jensen TH, Henriksen SL, Haastrup PF, Larsen PV, Søndergaard J, Jarbøl DE. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. *Scand J Gastroenterol*. 2015 Feb;50(2):162-9.
69. Reshetnikov OV, Kurilovich SA, Bobak M, et al. [Gastrointestinal symptoms in adult population of Novosibirsk city: prevalence and risk factors]. *Ter Arkh* 2009;81:11–16.
70. Saito YA, Locke GR, Talley NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. *Am J Gastroenterol* 2000;95:2816–2824.
71. Segal I. The irritable bowel syndrome in the black community. *S Afr Med J* 1984;65:73–74.
72. Soares RL, dos Santos JM, Rocha VR. Prevalence of irritable bowel syndrome in a Brazilian Amazon community. *Neurogastroenterol Motil* 2005;17:883.
73. Sperber AD, Shvartzman P, Friger M, et al. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the “true” prevalence of irritable bowel syndrome? *Eur J Gastroenterol Hepatol* 2007;19:441–447.
74. Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. *Am J Epidemiol* 1992;136:165–177.
75. Talley NJ, Fett SL, Zinsmeister AR, et al. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. *Gastroenterology* 1994;107:1040–1049.
76. Talley NJ, Zinsmeister AR, Melton LJ III. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. *Am J Epidemiol* 1995;142:76–83.
77. Talley NJ, Boyce PM, Owen BK, et al. Initial validation of a bowel symptom questionnaire and measurement of chronic gastrointestinal symptoms in Australians. *Aust N Z J Med* 1995;25:302–308.
78. Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. *Gut* 1997;41:394–398.
79. Thompson WG, Irvine EJ, Pare P, et al. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. *Dig Dis Sci* 2002;47:225–235.
80. Usai P, Manca R, Lai MA, et al. Prevalence of irritable bowel syndrome in Italian rural and urban areas. *Eur J Intern Med* 2010;21:324–326.
81. Vandvik PO, Lydersen S, Farup PG. Prevalence, comorbidity and impact of irritable bowel syndrome in Norway. *Scand J Gastroenterol*. 2006 Jun;41(6):650-6.
82. Walter SA, Kjellström L, Nyhlin H, et al. Assessment of normal bowel habits in the general adult population: the Popcol study. *Scand J Gastroenterol* 2010;45:556–566.
83. Wei X, Chen M, Wang J. [The epidemiology of irritable bowel syndrome and functional constipation of Guangzhou residents]. *Chin J Intern Med* 2001;40:517–520.

84. Whitehead WE, Winget C, Fedoravicius AS, et al. Learned illness behavior in patients with irritable bowel syndrome and peptic ulcer. *Dig Dis Sci* 1982;27:202–208.
85. Wilson S, Roberts L, Roalfe A, et al. Prevalence of irritable bowel syndrome: a community survey. *Br J Gen Pract* 2004;54:495–502.
86. Xiong LS, Chen MH, Chen HX, et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. *Aliment Pharmacol Ther* 2004;19:1217–1224.
87. Yilmaz S, Dursun M, Ertem M, et al. The epidemiological aspects of irritable bowel syndrome in southeastern Anatolia: a stratified randomised community-based study. *Int J Clin Pract* 2005;59:361–369.
88. Zagari RM, Law GR, Fuccio L, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. *Gastroenterology* 2010;138:1302–1311.
89. Zhao Y, Zou D, Wang R, et al. Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact. *Aliment Pharmacol Ther* 2010;32:562–572.